Trajectories of medication for opioid use disorder and their impact on HIV testing among people who inject drugs in India: A longitudinal assessment of clinic-based data

被引:0
|
作者
Mcfall, Allison M. [1 ]
Ganapathi, Lakshmi [2 ]
Gunaratne, Mihili P. [1 ]
Srikrishnan, Aylur K. [3 ]
Vasudevan, Conjeevaram K. [3 ]
Anand, Santhanam [4 ]
Solomon, Sunil S. [5 ]
Mehta, Shruti H. [1 ]
Lucas, Gregory M. [5 ]
机构
[1] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA
[2] Massachusetts Gen Hosp, Div Pediat Global Hlth, Boston, MA USA
[3] YR Gaitonde Ctr AIDS Res & Educ, Chennai, India
[4] A Square Consultancy, Chennai, India
[5] Johns Hopkins Univ, Infect Dis Dept, Sch Med, Baltimore, MD USA
关键词
India; HIV; HIV testing; medication for opioid use disorder; OST; People who inject drugs; trajectory; SUBSTITUTION TREATMENT; BUPRENORPHINE; THERAPY;
D O I
10.1111/add.16713
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
AimsThe aim of this study was to identify longitudinal trajectories of medication for opioid use disorder (MOUD) use throughout 1 year following MOUD initiation and to examine the association of trajectory membership with HIV testing among people who inject drugs in India.Design, setting and participantsThe study comprised group-based trajectory modeling using longitudinal clinic-based MOUD use data, set in seven Indian cities with integrated care centers (ICC) delivering MOUD, predominantly buprenorphine, in 2018-2019. A total of 1562 people who inject drugs who initiated MOUD for the first time at an ICC between 1 January 2018 and 31 December 2018 were included in this study. Median age was 26 years, 98% were male and 22% were living with HIV.MeasurementsDaily directly observed MOUD visits were biometrically verified and entered into an electronic database. A dichotomous variable for MOUD use each day throughout 1 year following initiation was created for the trajectory models. Client socio-demographics, HIV status and testing at the ICC and dose were extracted from the clinical database.FindingsWe found five MOUD trajectory groups: (1) early dropout (41%), (2) late dropout (18%), (3) delayed dropout (10%), (4) intermittent use (12%) and (5) persistent use (19%). Differences between the dropout groups were characterized by the rate of decline in MOUD use over time. The late dropout group had an 18% higher rate of HIV testing [adjusted rate ratio (aRR) = 1.18, 95% confidence interval (CI) = 1.10-1.27] and those with persistent MOUD use had a 91% higher rate of testing (aRR = 1.91, 95% CI = 1.77-2.05) compared with the early dropout group.ConclusionsNearly 70% of clients initiating medication for opioid use disorder (MOUD) at integrated care centers (ICCs) in India stop MOUD use within 1 year, with trajectories characterized by the rate of decline in engagement. Clients with better MOUD adherence appear to return more frequently for HIV testing at the ICCs, underscoring the value of integrated care models.
引用
收藏
页数:11
相关论文
共 30 条
  • [21] Willingness to use and distribute HIV self-testing kits among people who inject drugs in the San Diego-Tijuana border region
    Pines, Heather A.
    Eger, William H.
    Skaathun, Britt
    Vera, Carlos F.
    Harvey-Vera, Alicia
    Rangel, Gudelia
    Strathdee, Steffanie A.
    Bazzi, Angela R.
    HARM REDUCTION JOURNAL, 2024, 21 (01)
  • [22] LatinX harm reduction capital, medication for opioid use disorder, and nonfatal overdose: A structural equation model analysis among people who use drugs in Massachusetts
    Shrestha, Shikhar
    Stopka, Thomas J.
    Hughto, Jaclyn M. W.
    Case, Patricia
    Palacios, Wilson R.
    Reilly, Brittni
    Green, Traci C.
    DRUG AND ALCOHOL DEPENDENCE, 2024, 259
  • [23] Attitudes toward pharmacy-based HCV/HIV testing among people who use drugs in rural Kentucky
    Duong, Michelle
    Delcher, Chris
    Freeman, Patricia R.
    Young, April M.
    Cooper, Hannah L. F.
    JOURNAL OF RURAL HEALTH, 2022, 38 (01) : 93 - 99
  • [24] Integration of a geospatially targeted community-based testing approach with respondent-driven sampling to identify people who inject drugs living with HIV and HCV in Patti and Gorakhpur, India
    Loeb, Talia A.
    McFall, Allison M.
    Srikrishnan, Aylur K.
    Anand, Santhanam
    Vasudevan, Canjeevaram K.
    Mehta, Shruti H.
    Solomon, Sunil S.
    DRUG AND ALCOHOL DEPENDENCE, 2023, 247
  • [25] Changes in HIV care continuum indicators among community-based samples of HIV-infected people who inject drugs and men who have sex with men across 21 cities in India
    Menezes, Neia S. Prata
    Solomon, Sunil S.
    Mcfall, Allison M.
    Srikrishnan, Aylur K.
    Vasudevan, Canjeevaram K.
    Kumar, M. Suresh
    Celentano, David D.
    Mehta, Shruti H.
    Lucas, Gregory M.
    AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV, 2023, 35 (10): : 1570 - 1579
  • [26] Treatment of Hepatitis C virus among people who inject drugs at a syringe service program during the COVID-19 response: The potential role of telehealth, medications for opioid use disorder and minimal demands on patients
    Sivakumar, Anishaa
    Madden, Lynn
    DiDomizio, Elizabeth
    Eller, Anthony
    Villanueva, Merceditas
    Altice, Frederick L.
    INTERNATIONAL JOURNAL OF DRUG POLICY, 2022, 101
  • [27] Rates of perfect self-reported adherence to direct-acting antiviral therapy and its correlates among people who inject drugs on medications for opioid use disorder: The PREVAIL study
    Pericot-Valverde, Irene
    Rennert, Lior
    Heo, Moonseong
    Akiyama, Matthew J.
    Norton, Briana L.
    Agyemang, Linda
    Lumsden, Brandon
    Litwin, Alain H.
    JOURNAL OF VIRAL HEPATITIS, 2021, 28 (03) : 548 - 557
  • [28] Injection network drivers of HIV prevention service utilization among people who inject drugs: results of a community-based sociometric network cohort in New Delhi, India
    Menezes, Neia S. Prata
    Mehta, Shruti H.
    Wesolowski, Amy
    Clipman, Steven J.
    Srikrishnan, Aylur K.
    Kumar, Muniratnam S.
    Zook, Katie J. C.
    Lucas, Gregory M.
    Latkin, Carl
    Solomon, Sunil S.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 (04)
  • [29] Association between opioid agonist therapy use and HIV testing uptake among people who have recently injected drugs: a systematic review and meta-analysis
    Ferraro, Claire F.
    Stewart, Daniel E.
    Grebely, Jason
    Tran, Lucy T.
    Zhou, Shally
    Puca, Carla
    Hajarizadeh, Behzad
    Larney, Sarah
    Santo, Thomas, Jr.
    Higgins, Julian P. T.
    Vickerman, Peter
    Degenhardt, Louisa
    Hickman, Matthew
    French, Clare E.
    ADDICTION, 2021, 116 (07) : 1664 - 1676
  • [30] The Impact of Current Opioid Agonist Therapy on Hepatitis C Virus Treatment Initiation Among People Who Use Drugs From the Direct-acting Antiviral (DAA) Era: A Population-Based Study
    Bartlett, Sofia R.
    Wong, Stanley
    Yu, Amanda
    Pearce, Margo
    MacIsaac, Julia
    Nouch, Susan
    Adu, Prince
    Wilton, James
    Samji, Hasina
    Clementi, Emilia
    Velasquez, Hector
    Jeong, Dahn
    Binka, Mawuena
    Alvarez, Maria
    Wong, Jason
    Buxton, Jane
    Krajden, Mel
    Janjua, Naveed Z.
    CLINICAL INFECTIOUS DISEASES, 2022, 74 (04) : 575 - 583